Duodenal-jejunal bypass improves glycemia and decreases SGLT1-mediated glucose absorption in rats with streptozotocin-induced type 2 diabetes

Annals of Surgery

Volumn 258, Issue 1, 2013, Pages 89-97

  Jurowich, Christian Ferdinand ^a   Rikkala, Prashanth Reddy ^b   Thalheimer, Andreas ^a   Wichelmann, Christian ^a   Seyfried, Florian ^a   Sander, Victor ^a   Kreissl, Michael ^a   Germer, Christoph Thomas ^a   Koepsell, Hermann ^b   Otto, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Animals; Diabetes mellitus; Disease models; Duodenal jejunal bypass; Glucose tolerance test; Lewis rats

Indexed keywords

ALPHA METHYLGLUCOSIDE; C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 1; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; BRUSH BORDER; CONTROLLED STUDY; DOWN REGULATION; DUODENOJEJUNAL BYPASS; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTESTINE BYPASS; INTESTINE CELL; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH EMPTYING; STOMACH MOTILITY; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, EXPERIMENTAL; DUODENUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSE TOLERANCE TEST; JEJUNUM; MALE; RATS; RATS, INBRED LEW; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM-GLUCOSE TRANSPORTER 1;

EID: 84879087635     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182890311     Document Type: Article

References (55)

1. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724-1737.
2. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248-256.
3. Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond). 2009;33:S33-S40.
4. Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care. 2008;31:S290-S296.
5. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-323.
6. Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004;240:416-424.
7. Cohen R, Pinheiro JS, Correa JL, et al. Laparoscopic Roux-en-Y gastric bypass for BMI < 35 kg/m (2): a tailored approach. Surg Obes Relat Dis. 2006;2:401-404, discussion.
8. Strader AD, Vahl TP, Jandacek RJ, et al. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab. 2005;288:E447-E453.
9. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741-749.
10. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1-11.
11. Wang TT, Hu SY, Gao HD, et al. Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1. Ann Surg. 2008;247:968-975.
12. Patriti A, Aisa MC, Annetti C, et al. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Gotokakizaki rats through an enhanced Proglucagon gene expression and L-cell number. Surgery. 2007;142:74-85.
13. Pacebo D, De Luis DA, Romero A, et al. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg. 2007;194:221-224.
14. Kindel TL, Yoder SM, Seeley RJ, et al. Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptormediated mechanism. J Gastrointest Surg. 2009;13:1762-1772.
15. Bose M, Olivan B, Teixeira J, et al. Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? Obes Surg. 2009;19:217-229.
16. Speck M, Cho YM, Asadi A, et al. Duodenal-jejunal bypass protects GK rats from â-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. Am J Physiol Endocrinol Metab. 2011;300:E923-E932.
17. Salinari S, Bertuzzi A, Asnaghi S, et al. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care. 2009;32:375-380.
18. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439.
19. Brubaker PL. The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci. 2006;1070:10-26.
20. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-2157.
21. Gorboulev V, Scḧurmann A, Vallon V, et al. Na+-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2012;61:187-196.
22. Parker HE, Habib AM, Rogers GJ, et al. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia. 2009;52:289-298.
23. Reimann F, Habib AM, Tolhurst G, et al. Glucose sensing in L cells: a primary cell study. Cell Metab. 2008;8:532-539.
24. Shirazi-Beechey SP, Hirayama BA, Wang Y, et al. Ontogenic development of lamb intestinal sodium-glucose co-transporter is regulated by diet. J Physiol. 1991;437:699-708.
25. Ferraris RP, Diamond JM. Specific regulation of intestinal nutrient transporters by their dietary substrates. Annu Rev Physiol. 1989;51:125-141.
26. Dyer J, Wood IS, Palejwala A, et al. Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol. 2002;282:G241-G248.
27. Dyer J, Garner A, Wood IS, et al. Changes in the levels of intestinal Na+/glucose co-transporter (SGLT1) in experimental diabetes. Biochem Soc Trans. 1997;25:479S.
28. Fedorak RN, Cheeseman CI, Thomson A B R, et al. Altered glucose carrier expression: mechanism of intestinal adaptation during streptozocin-induced diabetes in rats. Am J Physiol. 1991;261:G585-G591.
29. Balen D, Ljubojevic M, Breljak D, et al. Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Physiol Cell Physiol. 2008;295:C475-C489.
30. Yoshida A, Takata K, Kasahara T, et al. Immunohistochemical localization of Na+-dependent glucose transporter in the rat digestive tract. Histochem J 1995;27:420-426.
31. Yoshikawa T, Inoue R, Matsumoto M, et al. Comparative expression of hexose transporters (SGLT1, GLUT1, GLUT2 and GLUT5) throughout the mouse gastrointestinal tract. Histochem Cell Biol. 2011;135:183-194.
32. Balakrishnan A, Stearns AT, Rounds J, et al. Diurnal rhythmicity in glucose uptake is mediated by temporal periodicity in the expression of the sodiumglucose cotransporter (SGLT1). Surgery. 2008;143:813-818.
33. Stearns AT, Balakrishnan A, Rhoads DB, et al. Diurnal expression of the rat intestinal sodium-glucose cotransporter 1 (SGLT1) is independent of local luminal factors. Surgery. 2009;145:294-302.
34. Balakrishnan A, Stearns AT, Ashley SW, et al. Restricted feeding phase shifts clock gene and sodium glucose cotransporter 1 (SGLT1) expression in rats. J Nutr. 2010;140:1-7.
35. Houghton SG, Iqbal CW, Duenes JA, et al. Coordinated, diurnal hexose transporter expression in rat small bowel: implications for small bowel resection. Surgery. 2008;143:79-93.
36. Junod A, Lambert AE, Stauffacher W, et al. Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest. 1969;48:2129-2139.
37. Zhang M, Lv X-Y, Li J, et al. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res. 2008;2008:1-9.
38. Srinivasan K, Viswanad B, Asrat L, et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005;52:313-320.
39. Haruta S, Kawai K, Jinnouchi S, et al. Evaluation of absorption kinetics of orally administered theophylline in rats based on gastrointestinal transit monitoring by gamma scintigraphy. J Pharm Sci. 2001;90:464-473.
40. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of realtime quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.
41. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
42. Puri ML, Sen PK. Analysis of covariance based on general ranc scores. Ann Math Statist. 1969;40:610-618.
43. Breen DM, Rasmussen BA, Kokorovic A, et al. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med. 2012;18:950-955.
44. Garvin TP, Sloan RC, III, Reed L M A, et al. Duodenal-jejunal bypass surgery does not increase skeletal muscle insulin signal transduction or glucose disposal in Goto-Kakizaki type 2 diabetic rats. Obes Surg. 2011;21:231-237.
45. Kindel DL, Martins P J F, Yoder SM, et al. Bypassing the duodenum does not improve insulin resistance associated with diet-induced obesity in rodents. Obesity. 2011;19:380-387
46. Strader AD, Clausen TR, Goodin SZ, et al. Ileal interposition improves glucose tolerance in low dose streptozotocin-treated diabetic and euglycemic rats. Obes Surg. 2009;19:96-104.
47. Stearns AT, Balakrishnan A, Tavakkolizadeh A. Impact of Roux-en-Y gastric bypass surgery on rat intestinal glucose transport. Am J Physiol Gastrointest Liver Physiol. 2009;297:G950-G957.
48. Osswald C, Baumgarten K, Sẗumpel F, et al. Mice without the regulator gene Rsc1A1 exhibit increased Na+-D-glucose cotransport in small intestine and develop obesity. Mol Cell Biol. 2005;25:78-87.
49. Kellett GL, Brot-Laroche E, Mace OJ, et al. Sugar absorption in the intestine: the role of GLUT2. Annu Rev Nutr. 2008;28:35-54.
50. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
51. Preitner F, Ibberson M, Franklin I, et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest. 2004;113:635-645.
52. Miyamoto K-I, Hase K, Takagi T, et al. Differential responses of intestinal glucose transporter mRNA transcripts to levels of dietary sugars. Biochem J. 1993;295(pt 1):211-215.
53. Burant CF, Flink S, De Paoli AM, et al. Small intestine hexose transport in experimental diabetes: increased transporter mRNA and protein expression in enterocytes. J Clin Invest. 1994;93:578-585.
54. Vernaleken A, Veyhl M, Gorboulev V, et al. Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007;282:28501-28513.
55. Sẗumpel F, Kucera T, Gardemann A, Jungermann K. Acute increase of portal insulin in intestinal glucose absorption via hepatoenteral nerves in the rat. Gastroenterology. 1996;110:1863-1869.